<SEC-DOCUMENT>0001213900-25-126812.txt : 20251231
<SEC-HEADER>0001213900-25-126812.hdr.sgml : 20251231
<ACCEPTANCE-DATETIME>20251231080008
ACCESSION NUMBER:		0001213900-25-126812
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20251231
DATE AS OF CHANGE:		20251231

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		251615744

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0271399-6k_ascent.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of <B>December 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53.3pt 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2025, Ascentage Pharma Group
International issued two announcements. The first is entitled &ldquo;(1) Change In Composition of Nomination Committee; (2)
Appointment of Lead Independent Non-Executive Director; (3) Establishment of Research and Development Committee; and (4)
Supplemental Announcement on Further Grant of Awards Under The 2022 RSU Scheme and Grant of Options Under The Post IPO Share Option
Scheme&rdquo;. The second is entitled &ldquo;List of directors and their roles and functions&rdquo;. A copy of the announcements is
furnished as Exhibits 99.1 and 99.2 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%">99.1</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%"><A HREF="ea027139901ex99-1_ascent.htm">Announcement dated December 30, 2025</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">99.2</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A HREF="ea027139901ex99-2_ascent.htm">Announcement dated December 30, 2025</A></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 31, 2025</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027139901ex99-1_ascent.htm
<DESCRIPTION>ANNOUNCEMENT DATED DECEMBER 30, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: right"><B>Exhibit
99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><I>Hong
Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.</I></P>

<P STYLE="margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">ASCENTAGE PHARMA GROUP INTERNATIONAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#20126;&#30427;&#37291;&#34277;&#38598;&#22296;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><I>(Incorporated in the Cayman Islands
with limited liability)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><B>(Stock Code: 6855)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"> <B>(1)</B> <B>CHANGE IN COMPOSITION OF NOMINATION COMMITTEE;</B></P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"> <B>(2)</B> <B>APPOINTMENT OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR;</B></P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"> <B>(3)</B> <B>ESTABLISHMENT OF RESEARCH AND DEVELOPMENT COMMITTEE; AND</B></P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>(4) SUPPLEMENTAL ANNOUNCEMENT ON FURTHER GRANT OF AWARDS UNDER THE 2022 RSU SCHEME AND GRANT OF OPTIONS UNDER
THE POST IPO SHARE OPTION SCHEME</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">CHANGE IN COMPOSITION OF THE NOMINATION
COMMITTEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The board (&ldquo;<B>Board</B>&rdquo;)
of directors (&ldquo;<B>Directors</B>&rdquo;) of Ascentage Pharma Group International (the &ldquo;<B>Company</B>&rdquo;) is pleased to
announce that with effect from December 26, 2025, Dr. Debra Yu will be appointed as an additional member of the nomination committee of
the Board (the &ldquo;<B>Nomination Committee</B>&rdquo;). Following the abovementioned appointment, the Nomination Committee shall comprise
Dr. David Sidransky as the chairman, and Mr. Ren Wei, Marc E. Lippman, MD and Dr. Debra Yu as members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">APPOINTMENT OF LEAD INDEPENDENT
NON-EXECUTIVE DIRECTOR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Board is pleased to announce that
with effect from December 26, 2025, Dr. David Sidransky will be appointed as the lead independent non-executive Director (the &ldquo;<B>Lead
INED</B>&rdquo;) to (i) serve as an intermediary for the other Directors and shareholders of the Company; and (ii) be available to other
Directors and shareholders of the Company where normal communication channels with the chairman of the Board or management of the Company
are inadequate. The Lead INED is not an executive position in the Company and does not have any management role in the Group, and will
not have a separate or higher level of responsibility or liability relative to the other independent non-executive Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>ESTABLISHMENT
OF THE RESEARCH AND DEVELOPMENT COMMITTEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Board is pleased to announce that
with effect from December 26, 2025, the research and development committee of the Board (the &ldquo;<B>Research and Development Committee</B>&rdquo;)
will be established. The Research and Development Committee shall consist of scientists, physicians, and business experts that oversee
R&amp;D strategy, pipeline, investments, and emerging trends, ensuring alignment with the business while managing risks. The Research
and Development Committee shall comprise Marc E. Lippman, MD as the chairman, and Dr. David Sidransky and Dr. Wang Shaomeng as members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">SUPPLEMENTAL ANNOUNCEMENT ON THE
FURTHER GRANT OF AWARDS UNDER THE 2022 RSU SCHEME AND GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Reference is made to the announcement
of the Company dated November 27, 2025 (the &ldquo;<B>Announcement</B>&rdquo;) in relation to, among other things, (i) the further grant
of 2022 Awards to the 2022 Selected Persons under the 2022 RSU Scheme; and (ii) the grant of Options to the Option Grantees under the
Post IPO Share Option Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in
the Announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As disclosed in the Announcement, the
Board has proposed to grant 127,201 RSUs and 103,364 Options to Dr. Zhai Yifan (&ldquo;<B>Dr. Zhai</B>&rdquo;) under the 2022 RSU Scheme
and the Post IPO Share Option Scheme, respectively (the &ldquo;<B>Proposed Grant to Dr. Zhai</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Company would like to supplement
that, pursuant to Rule 17.04(3) of the Listing Rules, as the Proposed Grant to Dr. Zhai, a substantial shareholder of the Company, would
result in the Shares issued and to be issued in respect of all RSUs and Options granted (excluding any options and awards lapsed in accordance
with the terms of the share schemes adopted by the Company) to her in the 12-month period up to and including the date of the Proposed
Grant representing in aggregate over 0.1% of the total issued share capital of the Company (excluding treasury shares), the Proposed Grant
to Dr. Zhai as disclosed in the Announcement shall be subject to approval by the shareholders of the Company (the &ldquo;<B>Shareholders</B>&rdquo;)
in the manner set out in Rule 17.04(4) of the Listing Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Accordingly, the Company currently expects
to propose to have the Proposed Grant to Dr. Zhai approved by the Shareholders at its upcoming annual general meeting (the &ldquo;<B>AGM</B>&rdquo;),
while Dr. Zhai and her associates and all core connected persons of the Company shall abstain from voting in favour on the relevant resolution
at the AGM to be convened by the Company in due course. As a result, 23,836 RSUs proposed to be granted to Dr. Zhai Yifan under the 2022
Further Grant which was originally scheduled to vest on November 26, 2025, shall instead be postponed to vest on a date falling on or
after the approval of the Proposed Grant to Dr. Zhai at the AGM, while the vesting arrangements of the other RSUs and Options granted
to her shall remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A circular containing, among other things,
(i) details in respect of the Proposed Grant to Dr. Zhai; and (ii) a notice convening the AGM, will be despatched to the Shareholders
in due course.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This announcement is supplemental to
and should be read in conjunction with the Announcement. The above additional information does not affect other information and content
set out in the Announcement. Save as disclosed herein, the contents of the Announcement remain unchanged and shall continue to be valid
for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center">By order of the Board</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Ascentage Pharma Group International<BR>
 Dr. Yang Dajun</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: center; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: center; font-style: italic">Chairman and Executive Director</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Suzhou, the PRC, December 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As
at the date of this announcement, the Board is comprised of Dr. Yang Dajun, as chairman and executive Director, Dr. Wang Shaomeng and
Dr. Lu Simon Dazhong<FONT STYLE="font-size: 10pt"><SUP>Note</SUP></FONT> as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei,
Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><I>Note: Dr.
Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance
requirements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea027139901ex99-2_ascent.htm
<DESCRIPTION>ANNOUNCEMENT DATED DECEMBER 30, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASCENTAGE PHARMA GROUP INTERNATIONAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center">&#20126;&#30427;&#37291;&#34277;&#38598;&#22296;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><I>(Incorporated in the Cayman Islands
with limited liability)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><B>(Stock Code: 6855)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><B>List of directors and their roles
and functions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">The members of the board of directors (the &ldquo;<B>Board</B>&rdquo;)
of Ascentage Pharma Group International are set out below:</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Executive Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Dr. YANG Dajun <I>(Chairman)</I></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Non-executive
Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Dr. WANG Shaomeng</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Dr. LU Simon Dazhong</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Independent Non-executive
Directors&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Mr. YE Changqing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Mr. REN Wei</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Dr. David SIDRANSKY <I>(Lead independent non-executive director)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Ms. Marina S. BOZILENKO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Dr. Debra YU</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Marc E. LIPPMAN, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">There are three Board committees. The composition of each
of the Board committees is set out as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 52%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Board
Committee</B></P></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Audit</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><B>Committee</B></P></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Remuneration Committee</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Nomination Committee</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Research and Development Committee</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B>Director</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dr. YANG Dajun</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dr. WANG Shaomeng</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dr. LU Simon Dazhong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Mr. YE Changqing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mr. REN Wei</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dr. David SIDRANSKY</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ms. Marina S. BOZILENKO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dr. Debra YU</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Marc E. LIPPMAN, MD</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">M</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><I>Notes:</I></TD><TD STYLE="width: 0.25in">C</TD>
                                             <TD>Chairman of the relevant Board committees</TD>
                                             </TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>M</TD>
                                             <TD>Member of the relevant Board committees</TD>
                                             </TR>
                                                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Suzhou, People&rsquo;s Republic of China, December 30, 2025</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 /X# 2(  A$! Q$!_\0
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M4BI1>@4445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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BTM+&!(($^ZBC]?<^]6JX:]7VLW([*%+V<%$****Q-C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 /T# 2(  A$! Q$!_\0
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K]0*]-J*VMH;.VCM[>)(H8UVHB# 4>U2UP5JGM)N1VTJ?LX*(4445D:G_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
